Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07441252 · ClinicalTrials.gov registry record · Phase 2
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
A Phase 2 study of Overweight or Obesity and Elevated Liver Fat, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 7
- Study locations
NCT07441252: Recruiting Phase 2 study of Overweight or Obesity and Elevated Liver Fat, sponsored by Amgen.
NCT07441252 is a Phase 2 study of Overweight or Obesity and Elevated Liver Fat that is actively recruiting participants, run by Amgen. The registered enrollment target is 180 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07441252, a Phase 2 study of Overweight or Obesity and Elevated Liver Fat, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 7
- Study locations
Study Summary
The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and body weight in participants living with obesity or overweight and elevated liver fat content, when administered in conjunction with reduced-calorie diet and increased physical activity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Maridebart cafraglutide
Study Locations (7)
Arizona
- Arizona Clinical Trials - Chandler
- Medical Advancement Centers of Arizona - Phoenix
Florida
- Indago Research and Health Center - Hialeah
- Floridian Clinical Research LLC - Miami Lakes
Maryland
- Woodholme Gastroenterology Associates - Glen Burnie - Glen Burnie
Nevada
- Excel Clinical Research - Las Vegas
Texas
- McAllen Research - Pharr
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2026-03-05 |
| Est. Completion | 2027-12-22 |
| Phase | Phase 2 |
What NCT07441252 shows while recruiting
NCT07441252 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher).
The record links to 1 condition, with Overweight or Obesity and Elevated Liver Fat appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07441252 lists 7 locations in 5 states (Arizona, Florida, Maryland).
Frequently Asked Questions
What is clinical trial NCT07441252 about?
NCT07441252 is a clinical study titled "A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight". The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and body weight in participants living with obesity or overweight and elevated liver fat content, when administered in conjunction with reduced-calorie diet ...
What is the current status of trial NCT07441252?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2026-03-05. Estimated completion is 2027-12-22.
What conditions does trial NCT07441252 study?
This clinical trial studies the following conditions: Overweight or Obesity and Elevated Liver Fat.
What interventions are being tested in trial NCT07441252?
The interventions under investigation include: Placebo (DRUG), Maridebart cafraglutide (DRUG).
Who is sponsoring clinical trial NCT07441252?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07441252 being conducted?
This trial has 7 study locations across Arizona, Florida, Maryland, Nevada, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07441252's enrollment target sits among peer trials
180 365th of 2000 higher than 1,611 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI